Latest Commercialisation News

Biotron Limited has completed the initial safety phase of its lead Hepatitis B drug in animal studies, paving the way for efficacy testing in two distinct mouse models. This milestone marks a significant step forward in the company’s antiviral drug development program.

Adherium Limited has announced an accelerated non-renounceable entitlement offer to raise approximately A$4 million, issuing new shares and options to fund expansion and product development. The offer includes a Top-Up Facility and is partially underwritten, signaling a strategic push to scale its respiratory monitoring technology.

Fortifai Limited has successfully raised $2.3 million through an upsized share placement, aiming to bolster its AI Gaming Lab and technology partnerships. The capital injection will support ongoing operations and strategic growth initiatives.

Sparc Technologies has unveiled its first-of-its-kind photocatalytic water splitting pilot plant at the University of Adelaide, marking a key milestone in green hydrogen innovation. Commissioning is set to begin in July 2025, aiming to demonstrate a low-cost, modular alternative to traditional electrolysis.

Rhythm Biosciences has regained NATA accreditation for its geneType laboratory, a key step toward commercialising its ColoSTAT® cancer risk test as an in-house diagnostic.

Diatreme Resources has announced a substantial upgrade to its Northern Silica Project’s Si2 Deposit, increasing the Measured Mineral Resource by 278% to 187.5 million tonnes. This milestone sets the stage for an upcoming Pre-Feasibility Study targeting a long-life silica sand operation.

Magnetic Resources NL has announced a significant 22% increase in the Lady Julie Gold Project resource, now totaling 2.14 million ounces, boosting the overall Laverton region resource to 2.32 million ounces. This upgrade reflects enhanced confidence in mineral continuity and advances the project closer to development.

Eden Innovations is set to consolidate its shares and launch a $6.6 million entitlement offer to reduce debt and fund global expansion of its EdenCrete® and OptiBlend® products.

Argenica Therapeutics has won up to $1.5 million in non-dilutive government funding to support its late-stage clinical trial of ARG-007, a promising treatment for acute ischaemic stroke.

Proteomics International has launched PromarkerD, a pioneering blood test that predicts diabetic kidney disease years before symptoms, marking its entry into the vast US healthcare market.

Provaris Energy has signed a pivotal Memorandum of Understanding with global shipping giant K LINE to advance the commercialisation of compressed hydrogen carriers, targeting Europe's growing hydrogen import demand by 2030.

Orthocell’s new study confirms Remplir™ delivers superior nerve regeneration and faster muscle recovery compared to traditional sutures, bolstering its US market rollout plans.